ストックスクリーナーアプリを入手
3.16
4.53%
-0.15
プレマーケット:
3.17
0.010
+0.32%
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move? - Sahm
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
RXRX|Recursion Pharmaceuticals Inc|Price:3.160|Chg%:-0.150 - TradingKey
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Recursion Pharmaceuticals Stock Short Interest Rises to 35.35% - Moomoo
Jim Cramer: Utilities Stocks 'Oversold,' Fastly 'Back From Abyss'Cloudflare (NYSE:NET), Akamai Technol - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
$Recursion Pharmaceuticals (RXRX.US)$ panic selling by retail investors... [Awkward] - Moomoo
Recursion (RXRX) Q2 2026 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Pipeline Catalysts - Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Institutional Ownership 2026 $RXRX - MarketBeat
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech) - 24/7 Wall St.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside of Over 120% Sparks Investor Interest - DirectorsTalk Interviews
Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships. - Pluang
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss - Sahm
What Does The Future Hold For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)? These Analysts Have Been Cutting Their Estimates - Moomoo
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 19% - simplywall.st
Recursion Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-08-09 - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals (RXRX) Reported Q2 Revenue Pressure, Is The Valuation Gap Too Wide? - simplywall.st
Recursion Pharmaceuticals director Blake Borgeson sells $97,500 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals Inc (RXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Recursion Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Recursion Pharmaceuticals Inc (RXRX) Stock Analysis & Forecast - TradingKey
Recursion Pharmaceuticals (RXRX) Director Blake Borgeson Sells 3 - GuruFocus
Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals Insiders Sell US$790k Of Stock, Possibly Signalling Caution - Moomoo
Bank of New York Mellon Corp Boosts Stake in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock Looks Weak On Returns While Trading Above Fair Value - simplywall.st
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Recursion Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Recursion Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Recursion misses Q2 2026 revenue forecast, shares fall premarket - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down Following Weak Earnings - MarketBeat
Recursion Pharmaceuticals Shares Fall After Q2 Miss - marketscreener.com
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update - Yahoo Finance
Earnings Flash (RXRX) Recursion Pharmaceuticals Inc Reports Q2 Revenue $7.7M - marketscreener.com
Recursion Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Recursion Pharmaceuticals 2026: Revenue $7.67M, EPS ($0.25) — 10-Q Summary - TradingView
Recursion Pharmaceuticals (NASDAQ: RXRX) gains Genentech milestone, highlights FAP drug progress - Stock Titan
Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q2 2026 -- GF Value Sees 43% Upside - GuruFocus
Recursion Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Recursion Pharmaceuticals in focus as earnings test AI promise By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals in focus as earnings test AI promise - Investing.com
Renaissance Technologies LLC Makes New $7.37 Million Investment in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals (RXRX): Investor Outlook on a Biotech Pioneer with 127.99% Potential Upside - DirectorsTalk Interviews
Recursion Pharmaceuticals Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
First Trust Advisors LP Has $8.02 Million Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline and Recent Financial Results - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Expected to Post Earnings on Tuesday - MarketBeat
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance Singapore
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – BIVA:RXRX - TradingView
RXRX (RXRX) insider details 50,000-share planned sale and recent stock trades - Stock Titan
RXRX|Recursion Pharmaceuticals Inc|Price:3.030| - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Cash Flow - TradingKey
AI Stocks: Why Tempus AI (NASDAQ:TEM), Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrodinger (NASDAQ:SDGR) Are in Focus - Kalkine Media
TradingKey - TradingKey
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):